Goldstein: Expect More Litigation After Myriad

June 13 (Bloomberg Law) -- Tom Goldstein, partner at Goldstein & Russell, PC and founder of SCOTUSblog, talks with Bloomberg Law's Lee Pacchia about the United States Supreme Court's decision in the Association for Molecular Pathology v. Myriad Genetics, Inc. case. At issue was whether patents may be granted on parts of the human body. He also explores whether Justice Scalia's concurrence raises doubts whether he believes in molecular biology, and where patent litigation will head in the wake of the decision. Bloomberg Law is a sponsor of SCOTUSblog.
Liquidity-Hooked Bond Buyers Take Action to Protect Funds
49:40 - Bond-fund managers may debate the exact reason for the deterioration in market liquidity, but one thing is clear: they’re highly concerned about it. Bloomberg's Lisa Abramowicz has more on "Bloomberg Markets." (Source: Bloomberg)
  • The Strange Final Hour of Trading in China Stocks
  • Should Investors Focus on Facebook’s Active Users?
  • Facebook Has Solid Numbers Across the Board: Pyykkonen